Lin Patrick 4

What Happened
Lin Patrick, listed as Processa Pharmaceuticals' Chief Business - Strategy Off, reported an insider purchase of 1,831 shares. The transaction was reported as a purchase (code P) at $2.22 per share for a total cost of approximately $4,065. This is a straightforward buy (potentially a modest bullish signal), not a sale or option exercise.

Key Details

• Transaction date: 2026-06-15; Report filed: 2026-06-16 (timely filing).
• Price and amount: 1,831 shares @ $2.22 each = ~$4,065.
• Transaction type: Purchase (P) — reported as open-market or private purchase.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes / plans: No 10b5-1 plan, tax-withholding, or other footnotes noted in the provided data.
• Filing timeliness: Filed the next day — appears timely under Form 4 reporting rules.

Context
This is a small-dollar insider purchase (roughly $4k), which is typically more informative than a sale but should be viewed alongside other insider transactions and company news. The filing shows a simple buy; there is no indication of option exercises, gifts, or tax withholdings in the supplied details.